Noble Financial restated their buy rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in a report released on Sunday, May 14th.
AVXL has been the subject of a number of other research reports. Maxim Group set a $15.00 price target on Anavex Life Sciences Corp. and gave the company a buy rating in a research report on Thursday, January 19th. Zacks Investment Research raised Anavex Life Sciences Corp. from a hold rating to a buy rating and set a $7.00 price target for the company in a research report on Wednesday, April 12th.
Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 6.14 on Friday. The company’s market capitalization is $254.05 million. Anavex Life Sciences Corp. has a 12 month low of $2.43 and a 12 month high of $8.30. The stock’s 50 day moving average price is $5.82 and its 200-day moving average price is $5.08.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/06/03/anavex-life-sciences-corp-avxl-rating-reiterated-by-noble-financial-updated-updated.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVXL. State Street Corp raised its position in Anavex Life Sciences Corp. by 27.2% in the fourth quarter. State Street Corp now owns 391,065 shares of the biotechnology company’s stock worth $1,549,000 after buying an additional 83,716 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in Anavex Life Sciences Corp. during the fourth quarter worth $151,000. Edge Wealth Management LLC purchased a new position in Anavex Life Sciences Corp. during the first quarter worth $230,000. Park West Asset Management LLC increased its position in Anavex Life Sciences Corp. by 97.5% in the first quarter. Park West Asset Management LLC now owns 2,962,090 shares of the biotechnology company’s stock worth $17,002,000 after buying an additional 1,462,090 shares during the period. Finally, Bank of America Corp DE increased its position in Anavex Life Sciences Corp. by 12.9% in the first quarter. Bank of America Corp DE now owns 39,981 shares of the biotechnology company’s stock worth $229,000 after buying an additional 4,561 shares during the period. 11.59% of the stock is owned by institutional investors and hedge funds.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
What are top analysts saying about Anavex Life Sciences Corp.? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Anavex Life Sciences Corp. and related companies.